Abstract
Eosinophils are major pro-inflammatory cells that make a major contribution to diseases that affect the upper and lower airways, skin and gastrointestinal tract. Interleukin (IL)-5 is central to their maturation and release from the bone marrow together with their subsequent accumulation and activation in the tissues. Mepolizumab is a humanized monoclonal antibody (mAb) with potent IL-5 neutralizing effects that represents a potential treatment for eosinophilic diseases. Several clinical trials with mepolizumab reported that treatment of patients with mild to severe asthma resulted in a substantial reduction in blood and sputum eosinophil numbers. However, clinical outcomes were disappointing as there were no significant effects on airway hyper-reactivity or the late asthmatic reaction to inhaled allergen challenge. More recently two studies, one in patients with refractory eosinophilic asthma with a history of recurrent severe exacerbations and the other in patients with persistent sputum eosinophilia and symptoms despite systemic treatment with prednisone treatment, reported that monthly intravenous mepolizumab reduced sputum/blood eosinophilia, asthma exacerbations together with improvments in quality of life. Mepolizumab also appears to be an effective therapy for hypereosinophilic syndrome while other trials have shown efficacy of mepolizumab therapy in eosinophilic esophagitis. This review will consider the current status of the clinical development of mepolizumab for diseases with a significant eosinophilic component to their pathology.
Keywords: Mepolizumab, IL-5, Eosinophils, Asthma, Eosinophilic esophagitis, Hypereosinophilic syndrome
Current Medicinal Chemistry
Title: Mepolizumab and Eosinophil-Mediated Disease
Volume: 16 Issue: 36
Author(s): G. M. Walsh
Affiliation:
Keywords: Mepolizumab, IL-5, Eosinophils, Asthma, Eosinophilic esophagitis, Hypereosinophilic syndrome
Abstract: Eosinophils are major pro-inflammatory cells that make a major contribution to diseases that affect the upper and lower airways, skin and gastrointestinal tract. Interleukin (IL)-5 is central to their maturation and release from the bone marrow together with their subsequent accumulation and activation in the tissues. Mepolizumab is a humanized monoclonal antibody (mAb) with potent IL-5 neutralizing effects that represents a potential treatment for eosinophilic diseases. Several clinical trials with mepolizumab reported that treatment of patients with mild to severe asthma resulted in a substantial reduction in blood and sputum eosinophil numbers. However, clinical outcomes were disappointing as there were no significant effects on airway hyper-reactivity or the late asthmatic reaction to inhaled allergen challenge. More recently two studies, one in patients with refractory eosinophilic asthma with a history of recurrent severe exacerbations and the other in patients with persistent sputum eosinophilia and symptoms despite systemic treatment with prednisone treatment, reported that monthly intravenous mepolizumab reduced sputum/blood eosinophilia, asthma exacerbations together with improvments in quality of life. Mepolizumab also appears to be an effective therapy for hypereosinophilic syndrome while other trials have shown efficacy of mepolizumab therapy in eosinophilic esophagitis. This review will consider the current status of the clinical development of mepolizumab for diseases with a significant eosinophilic component to their pathology.
Export Options
About this article
Cite this article as:
Walsh M. G., Mepolizumab and Eosinophil-Mediated Disease, Current Medicinal Chemistry 2009; 16 (36) . https://dx.doi.org/10.2174/092986709789909639
DOI https://dx.doi.org/10.2174/092986709789909639 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial from Editor-in-Chief: Alternative and Complementary Medicine in Pulmonary Conditions
Current Respiratory Medicine Reviews Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical Based Evidence
Current Pharmaceutical Design Effect of Antenatal Steroids on Haemodynamics in the Normally Grown and Growth Restricted Fetus
Current Pediatric Reviews Breaking the Skin Barrier: Achievements and Future Directions
Current Pharmaceutical Design Alpha-1-Antitrypsin Deficiency and Mechanisms of Liver Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry From Adipose Tissue Protein Secretion to Adipopharmacology of Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Biological Activities and Corresponding SARs of Andrographolide and Its Derivatives
Mini-Reviews in Medicinal Chemistry Meet the Guest Editor
Combinatorial Chemistry & High Throughput Screening Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Glucocorticoid Receptor Interacting Co-regulators: Putative Candidates for Future Drug Targeting Therapy
Mini-Reviews in Medicinal Chemistry Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry The Risk of Adverse Drug Reactions in Older Patients: Beyond Drug Metabolism
Current Drug Metabolism A Review on Defects of Dendritic Cells in Common Variable Immunodeficiency
Endocrine, Metabolic & Immune Disorders - Drug Targets Pediatric Eosinophilic Esophagitis: Epidemiology, Diagnosis and Treatment
Current Pediatric Reviews Knemometry for Assessment of Growth Suppressive Effects of Exogenous Glucocorticoids
Current Pediatric Reviews Adverse Systemic Reactions of Antihistamines: Highlights in Sedating Effects, Cardiotoxicity and Drug Interactions
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Exhaled Breath Biomarkers in Asthmatic Children
Inflammation & Allergy - Drug Targets (Discontinued) The Guinea Pig as an Animal Model for Asthma
Current Drug Targets